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Little is known about the shot potency and dose consistency of many of the inhalers in common use, and until 
recently there has been little consensus over the best way to evaluate these parameters. Since marked effects can be 
achieved with the inhaled route, more information is needed about the dosing characteristics of all available inhalers. 
As there are now two multidose powder inhalers available in the U.K. capable of supplying 1 month or more of 
treatment, this study was designed to compare the delivery characteristics of these two dry powder inhalers 
delivering glucocorticosteroids. The method used was in vitro analysis of the emitted dose and fine particle fraction 
throughout the life of five of each type of device. The multidose powder inhaler delivered between 87 and 93% of the 
label claim dosage, whilst the reservoir device delivered 40-58%. There was no fall off of shot potency towards the 
end of either device’s life. Fine particle fraction for the multidose and reservoir systems, was 21 and 18%, 
respectively, at 60 1 min - ’ flow, but fell to 16 and 6% at 28.3 1 min-‘. 
In conclusion, there were statistically significant differences (P<O.OOOl) in the drug emission of both dose and fine 
particle fraction of these two powder inhalers. 
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Introduction 
Although metered-dose inhalers remain the most frequently 
prescribed delivery system for the treatment of asthma (l), 
dry powder inhalers have an established place. Their par- 
ticular value is perceived to be in improving drug targeting 
in the airway by avoiding the necessity for accurate patient 
co-ordination in firing a device and inhaling from it. All 
powder devices currently available work by passively liber- 
ating powder into the airstream during the patient’s inspi- 
ration. The first such device was the Spinhaler@ (Fisons), 
followed by Ventolin@ and Becotide@ Rotahalers@ 
(Glaxo) and Inhalator@ (Boehringer-Ingelheim). These 
devices all use capsules containing a single dose to be 
individually loaded by the patient for each inhalation. More 
recently, multidose systems have been developed which 
incorporate several day’s treatment (Diskhale@, Glaxo) 
and a reservoir system which provides at least 1 month’s 
treatment (Turbuhale?, Astra). This reservoir device (RD) 
incorporates a metering unit fed from a drug reservoir, 
which is charged by the patient twisting the base of the 
device. The Diskus@ is a multidose powder inhaler (MD) 
(currently available in the U.K. as Accuhaler@, Glaxo 
Wellcome) which uses 60 individual factory measured and 
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sealed doses within blisters in a foil strip which are opened 
in turn as the device is prepared for inhalation. 
Materials and Methods 
Five inhalers from a single batch of each product were 
obtained for this study. 
A protocol was designed to test, using in vitro methods, 
the total dose delivered ex-device at nominal airflow rates 
of 30, 60 and 901 min-‘, and the fine particle fraction of 
the drug at nominal airflow rates of 28.3 and 60 1 min ~ I, at 
regular intervals throughout the life of each inhaler. Iden- 
tical protocols were used for the two inhaler types, and 
testing was randomized as far as practicable to cover the 
entire range of doses, with all untested doses being drawn to 
waste at 60 1 min - I. 
Each Diskus@ was tested in parallel with the corre- 
sponding Turbuhaler@ device by the same analyst (Herd 
Mundy Richardson Ltd., Lancashire, U.K.), and the 
analyses were completed more than 6 months before either 
expiry date. 
DETERMINATION OF THE DOSE DELIVERED 
EX-DEVICE 
The dose delivered ex-device was determined by drawing 
individual doses from each inhaler through separate GO120 
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TABLE 1. Devices compared 
Product Batch Expiry 
Flixotide@ 
250 iug 
Pulmicort@ 
200 Pug 
Disk@ 
Turbohaler@ 
Lot E94L24 19 
Lot UL 408 
March 1996 
November 1996 
TABLE 2(a). Protocol summary for MD (device contains 60 doses) 
Product Flixotide@ Diskus@ 250 pug 
Inhaler number 1 2 3 4 1 5 
Test Dose numbers tested 
Doses tested ~ at 30 1 min ’ 1, 2, 19, 20, 1, 2, 19, 20, 5, 6, 12, 13, 3, 4, 15, 16, 3, 4, 15, 16, 
36, 31, 44, 36, 37, 44, 32, 33, 39, 32, 33, 39, 32, 33, 39, 
45, 54, 55 45, 54, 55 40, 59, 60 40, 56, 57 40, 56, 57 
Doses tested - at 60 1 min ’ 4, 5, 22, 23, 4, 5, 22, 23, 3, 4, 10, 11, 1, 2, 13, 14, 1, 2, 13, 14, 
39, 40, 47, 39, 40, 47, 28, 29, 48, 30, 31, 37, 30, 31, 37, 
48, 57, 58 48, 57, 58 49, 51, 58 38, 59, 60 38, 59, 60 
Doses tested - at 90 1 min ’ 6, 7, 24, 25, 6, 7, 24, 25, 1, 2, 8, 9, 6, 7, 18, 19, 6, 7, 18, 19, 
41, 42, 49, 41, 42, 49, 26, 27, 46, 35, 36, 42, 35, 36, 42, 
50, 59, 60 50, 59, 60 47, 55, 56 43, 54, 55 43, 54, 55 
Fine particle fraction doses at 28.3 1 min ~ ’ 8817 8-17 15-24 44-53 4453 
Fine particle fraction doses at 60 1 min - 1 26-35 26-35 3645 20-29 20-29 
TABLE 2(b). Protocol summary for RD (device contains 100 doses) 
Product Pulmicort@ Turbuhaler@ 200 pg 
Inhaler number 1 2 3 4 5 
Test Dose numbers tested 
Doses tested ~ at 30 1 min ’ 1, 2, 31, 32, 1, 2, 31, 32, 
59,60, 13, 59, 60, 73, 
74, 90, 91 74, 90, 91 
Doses tested - at 60 1 min ’ 6, 7, 36, 37, 6, 7, 36, 37, 
64, 65, 78, 64, 65, 78, 
79, 95, 96 79, 95, 96 
Doses tested - at 90 1 min ’ 10, 11, 40, 10, 11, 40, 
41, 68, 69, 41, 68, 69, 
82, 83, 99, 82, 83, 99, 
100 100 
Fine particle fraction doses at 28.3 1 min ~ ’ 13322 13322 
Fine particle fraction doses at 60 1 min - ’ 43352 43-52 
8, 9, 19, 20, 
49, 50, 83, 
84, 99, 100 
4, 5, 16, 17, 
46, 47, 79, 
80, 94, 95 
1, 2, 13, 14, 
43, 44, 16, 
77, 91, 92 
24-33 
59-68 
4, 5, 24, 25, 4, 5, 24, 25, 
53, 54, 66, 53, 54, 66, 
67, 93, 94 61, 93, 94 
1, 2, 21, 22, 1, 2, 21, 22, 
49, 50, 61, 49, 50, 61, 
62, 99, 100 62, 99, 100 
9, 10, 29, 9, 10, 29, 
30, 58, 59, 30, 58. 59. 
69, 70, 89, 69, 70, 89, 
90 90 
73-82 73-82 
3342 3342 
30 
g - 25 
B 
8 20 
g 2 15 
E 
10 
TABLE 3. Mixed solvents and HPLC conditions 
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Flixotide Disk@ Pulmicort Turbuhaler@ 
250 Pg 200 !a 
Mixed solvent 
HPLC column 
65:35(h) 70:30 (v/v) 
acetonitrile:water methanol:water 
20 cm x 4.6 mm id. 20 cm x 4.6 mm i.d. 
5pm Spherisorb ODSl 5 pm Hypersil ODS 
Mobile phase 
Flow rate 
Injection volume 
Temperature 
Detection 
Measurement 
Quantitation 
50:15:35 (v/v) 
methanokacetonitrile: 
0.01 M aqueous ammonium dihydrogen 
orthophosphate (adjusted to pH 3.5 with 
10% v/v aqueous orthophosphoric acid) 
1.5mlmin-’ 
5Opl 
40°C 
UV at 239 nm 
Peak area 
External standard 
60:40 (v/v) 
acetonitrile:water 
1.5 ml mini 
100~1 
Room temperature 
UV at 239 nm 
Peak area 
External standard 
5 20 35 50 65 80 95 5 20 35 50 65 80 
% label claim % label claim 
n MD (n = 50) n MD(n=50) 
q RD(n=49) q RD(n=50) 
g 
25 
n 
35 
30 
3 
- 25 
6 
g 20 
g 2 15 
h 
10 / 
5 20 35 50 65 80 95 
% label claim 
n MD (n = 48) 
0 RD (n = 49) 
FIG. 1. Frequency distribution of the doses delivered at (a) 30, (b) 60 and (c) 90 1 min ~ i. 
Filtrete@ (3M U.K. plc, 3M House, Bracknell, Berks., 
RG12 lJU, U.K.) electrostatic filters at 30, 60 and 90 1 
min ~ ’ (Fig. 1). The filter medium combines high efficiency 
with a very low resistance to air flow (a pressure drop of 
~0.05 kPa is expected when air is drawn through the filter 
at 60 1 min - I). Each dose was recovered from the filter and 
analysed using the mixed solvent and high-performance 
liquid chromatography (HPLC) conditions referenced in 
Table 3. The mixed solvent was chosen to be compatible 
with the HPLC conditions, and has been shown to achieve 
>95% recovery from the filter with each drug. 
DETERMINATION OF THE FINE PARTICLE 
FRACTION OF THE DELIVERED DRUG 
preseparator and metal throat (with identical volume to the 
Twin Impinger throat described in Apparatus A, B.P. 1993, 
Appendix XVIIC, figure 2). Ten consecutive doses from 
each inhaler were drawn through the Cascade Impactor 
(C.I.) at either 28.3 or 60 1 min- ‘, the impactor was 
dismantled, the drug was recovered from each stage and 
was analysed by HPLC. The C.I. plates were coated with 
silicone oil by immersion in a 1% solution of silicone oil in 
hexane, and then being allowed to dry prior to each 
analysis. For both tests, each dose was collected using the 
appropriate flow rate by switching a pump on for 3 s using 
a timing device. The same pumps, timers and apparatus 
were used for both devices. The flow rates of 28.3 and 
60 lmin - ’ are the standard calibration flow rates for the 
Anderson impactor. 
The fine particle fraction of the delivered drug was deter- The doses following a test at 30 or 28.3 1 min - ’ were 
mined using a Cascade Impactor [Anderson 1ACFM drawn to waste at 60 1 min - ’ to remove any material left in 
Ambient (non-viable)] with impaction plates, high capacity the mouthpiece that might bias later results. The results are 
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TABLE 4. Fine particle fraction of the delivered drug Discussion 
Fine particle fraction This study was designed to directly compare the drug 
(% label claim) delivery characteristics in respect of the variability and 
Flow rate % of doses Multidose Reservoir 
(1 min - ‘) remaining device device 
28.3 
Mean (n = 5) 
60 
Mean (n=5) 
88 (n=2) 18, 16 7, 7 
71 (n= 1) 15 8 
28 (n=2) 15, 15 3, 5 
16 6 
68 (n=2) 22, 22 17,21 
58 (n=2) 22, 21 21, 14 
42 (n= 1) 20 19 
21 18 
Relative standard deviation 
combined across flow rates 
(n= 10) 0.6 2.8 
all expressed in relation to the nominal (label claim) dose 
rather than in relation to the total drug recovered. 
STATISTICAL METHODS 
Variabilities and means are compared using the F-test and 
Student’s t-test, respectively. 
Results 
Figure 1 displays the dose consistency for the two types of 
inhaler at 30,60 and 90 1 min - i. At each flow rate, the MD 
delivered a consistently higher proportion of the nominal 
dose. The variability of the MD (relative standard deviation 
3.4, with 95% confidence limits of 3.1-3.9) was significantly 
lower than the variability of the RD (relative standard 
deviation 14.6 with 95% confidence limits of 12.8-16.3) 
(PcO.0001) and this was consistent for each flow rate. 
The MD showed little change in the dose delivered at 
either 30, 60 or 90 1 min - ’ delivering 87, 90 and 93% of the 
nominal dose, respectively. By comparison, the RED deliv- 
ered significantly lower proportions for each of the flows 
[40, 46 and 58%, of the nominal dose (P<O.OOOl in each 
case)]. 
Table 4 sets out the percentage of particles retrieved 
which were less than 6,~~um at the two flow rates of 2X.3 and 
601 min-‘. The MD displayed a fairly consistent fine 
particle fraction of 21% at 60 1 min- ‘, falling to 16% at 
28.3 1 min- i. The RD, however, demonstrated a greater 
fall in the fine particle fraction from 18% at 60 1 min ~ ’ to 
6% at 28.3 1 min- i. The variability of the MD (standard 
deviation 0.6, with 95% confidence limits of 0.4-1.8) was 
significantly less than the variability of the RD (standard 
deviation 2.8, with 95% confidence limits of 1.6 to 7.9) 
(P=O.O148). 
precision of the delivered dose and also the fine particle 
fraction from the reservoir and multidose devices for the 
glucocorticoids budesonide and fluticasone propionate, 
respectively. It is of importance to understand the drug 
delivery characteristics of currently available inhalers with 
respect to delivered dose and fine particle fraction, and view 
them alongside the pharmacological profile of the drugs 
that they deliver (2). Lipworth has observed that there is 
accumulating evidence to suggest that absorption across the 
lung vascular bed is an important determinant of systemic 
bioactivity and potential adverse effects, and this is particu- 
larly relevant with inhaled glucocorticoids where there may 
be little or no first-pass metabolism in the lung despite 
extensive first-pass metabolism in the liver (3). Inhaled 
steroids are given for many years and dose minimization 
would seem a sensible aim; it would seem axiomatic that an 
inhaler designed to improve drug targeting and compliance 
in asthma treatment should perform consistently, delivering 
a reliably constant dose in normal use. Since the air flow 
achieved through an inhaler will vary from patient to 
patient, consistency of dosing has been assessed using the 
three flow rates of 30, 60 and 90 1 min ‘. These rates 
correspond to the lower, middle and upper range of in- 
spiratory flow rates achieved by asthmatics, and are con- 
ventional study rates. A drawthrough time of 3 s has been 
used in a further effort to mimic patient usage. The fine 
particle fraction (l-6pm) has also been assessed at the 
calibration flow rates of 28.3 and 60 1 mini ’ using the 
Anderson eight-stage sampler which is considered to be 
the test device of choice (5). This fine particle fraction is 
thought to be deposited mainly in the lower airway of the 
lung, and is considered to be of the greatest clinical 
relevance therapeutically. Whilst it is accepted that the fine 
particle mass (FPM) is not a measure of lung deposition, it 
is generally agreed that it provides, the best estimate of the 
dose likely to reach the lungs (6). The present authors, 
findings for the emitted dose of budesonide from the 
Turbuhaler@ of 46.0 & 14.6% nominal (label claim) at a 60 1 
min - i flow rate are lower than that of Byron and Hindle 
(7), who found a mean emitted dose of budesonide of 
58.1 5 18.3%at60lmin-‘. Terbutaline data with the same 
device and protocol was 62.5 & 13.7%. Meakin et al. (8) 
reported a mean emitted dose of terbutaline from the 
Turbuhaler@ of about 75% of label claim at 60 1 min ~ ‘, 
with an emitted dose range of + 50%. He also found the 
emitted dose to be quite flow dependent; at 30 1 mini ‘, it 
fell to two-thirds of that achieved at 60 1; min - ‘. Hindle 
et al. (9) reported an emitted dose of budesonide of 
63.0 & 17.4% at 60 1 min- ‘. Some of the studies reported 
above have used test volumes well in excess of what might 
be achieved by patients in use. Meakin et al. (8) tested at 
60+5lmin~’ for 10 s, giving a test volume of 5.5-6.5 1 for 
the assessment of emitted dose, and Hindle et al. (9) and 
Bryon et al. (7) used a test volume of 4 1 irrespective of flow 
rate for the emitted dose. However, Hindle et al. (9) used 
201 at 601 min-’ for the measurement of fine particle 
fraction, and the test volumes in the papers by Olssen et al. 
(11,15) and de Boer and Lerk (12) are not declared. In the 
present study, the Disk& which delivered between 87 and 
93% of the label claim across all three flow rates; with a 
relative standard deviation of 3.4 and confidence limits of 
3.1-3.9, performed acceptably when judged against the 
consensus statement recommendations (5), despite the low 
volumes used to test at the lower flow rates. (15.1 at 30 1 
min-‘,3~01at60lmin~‘and4~5lat90lmin-’).Under 
the same conditions, the Turbuhaler@ was much more 
variable in performance. The RSD was 14.6 with 95% 
confidence limits of 12.8-16.3, a difference which was highly 
statistically significant (P<O.OOOl). These other authors, 
findings; when taken in conjunction with the present obser- 
vations of a fall to 40% nominal dose emitted at 30 1 min - ‘, 
confirm a significant emitted dose variability from the 
Turbuhaler@. The reasons for the variation are not clear 
but could in part be attributable to the wide individual 
dose variability observed both here in other laboratories, 
which might be amplified by the use of different test 
volumes. Bisgaard (13) suggested that the low and variable 
delivery from the Turbuhaler in young children was due to 
the low flow rates generated, and, of course, such low flow 
rates are also paralleled by low volumes in viva. Certainly, 
although the present reported values are all lower numeri- 
cally than those published elsewhere, the results of this 
study are not inconsistent in that they demonstrate that the 
in vitro performance at the Turbuhaler@ is variable and 
that this effect is more marked at lower flow rates or 
volumes. 
The Diskus@ delivered a fine particle fraction of 21% of 
nominal dose at 60 1 min ~ ’ in 3 s, and the Turbuhale? 
delivered 18%. At 28.3 1 min- ’ (test volume 1.4 l), the 
values fell to 16 and 6%, respectively. There are also wide 
variations in data published elsewhere for the fine particle 
fraction obtained from the Turbuhaler@, ranging from 49% 
at 60 1 min - i (11) to 37% at 60 1 min - ’ (12). Meakin et al. 
(8) reported a three-fold reduction in the fine particle dose 
from the Turbuhaler (from 210 pg to 59 * 25 pug) by reduc- 
ing the flow rate from 60 to 30 1 min - ‘, which corresponds 
to a reduction in test volume from 20.0 to 10.0 1. Ifversen et 
al. (10) also found that the proportion of ~5 pm small 
particles at 30 1 min ~ i was 3 1% of the dose delivered at 60 1 
min-’ with the RD. Both present observations and pre- 
vious reports would be partly explicable by the variation in 
test volumes used in the different studies, and also by other 
findings by de Boer et al. (14) who demonstrated that the 
rate of flow increase during actuation had an important 
effect on the fine particle output from the Turbuhaler@‘. 
It is not clear from the present study why the RD delivers 
inconsistently when tested in vitro. Presumably this repre- 
sents difficulties with either the volumetric metering or 
particulate separation in the mouthpiece, or both. A sub- 
stantially lower test volume was used in this study com- 
pared to others so that any reduced emission at low flow 
rates is likely to be exaggerated. It is also possible that the 
rate of increase in flow has a more profound effect on the 
delivery through the Turbuhaler@ than the Diskus@. This 
possible effect was not able to be analysed here but does 
need to be addressed in future research. These findings, 
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which are based on test parameters which the authors argue 
are more clinically relevant, do raise the possibility that the 
conventional testing conditions (17) recommend the use of 
too large a test volume, thus obscuring appreciation of 
inadequate delivery characteristics in conditions close to the 
limit of functionality of the devices under test. 
Conclusions 
It is clear from this study that marked differences in 
performance exist between these two inhalers at all clini- 
cally relevant flow rates tested. The effect is more marked at 
the lower flow rates. 
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